

# Leon L Su

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1271136/publications.pdf>

Version: 2024-02-01

16  
papers

1,328  
citations

687363

13  
h-index

996975

15  
g-index

18  
all docs

18  
docs citations

18  
times ranked

1806  
citing authors

#	ARTICLE	IF	CITATIONS
1	Interleukin-2 superkines by computational design. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2117401119.	7.1	12
2	Facile discovery of surrogate cytokine agonists. Cell, 2022, 185, 1414-1430.e19.	28.9	33
3	Potentiating adoptive cell therapy using synthetic IL-9 receptors. Nature, 2022, 607, 360-365.	27.8	41
4	Structural basis for IL-12 and IL-23 receptor sharing reveals a gateway for shaping actions on T versus NK cells. Cell, 2021, 184, 983-999.e24.	28.9	78
5	Structure-based decoupling of the pro- and anti-inflammatory functions of interleukin-10. Science, 2021, 371, .	12.6	79
6	The tissue protective functions of interleukin-22 can be decoupled from pro-inflammatory actions through structure-based design. Immunity, 2021, 54, 660-672.e9.	14.3	36
7	Selective expansion of regulatory T cells using an orthogonal IL-2/IL-2 receptor system facilitates transplantation tolerance. Journal of Clinical Investigation, 2021, 131, .	8.2	46
8	Calibration of cell-intrinsic interleukin-2 response thresholds guides design of a regulatory T cell biased agonist. ELife, 2021, 10, .	6.0	23
9	Prevention of Acute Graft-Versus-Host Disease Using an Engineered Mouse Orthogonal IL-2/IL-2R <sup>2</sup> Regulatory T Cells. Blood, 2021, 138, 1688-1688.	1.4	0
10	A human orthogonal IL-2 and IL-2R <sup>2</sup> system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia. Science Translational Medicine, 2021, 13, eabg6986.	12.4	64
11	Immune receptor inhibition through enforced phosphatase recruitment. Nature, 2020, 586, 779-784.	27.8	59
12	Human Orthogonal IL-2/IL-2R <sup>2</sup> As a Tunable Approach to Enhance CD19-Specific CAR-T Cell Antitumor Activity. Blood, 2020, 136, 48-48.	1.4	1
13	Structure of the IFN <sup>3</sup> receptor complex guides design of biased agonists. Nature, 2019, 567, 56-60.	27.8	85
14	Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. Science, 2018, 359, 1037-1042.	12.6	254
15	Therapeutic Effects of Systemic Administration of Chaperone Î±B-Crystallin Associated with Binding Proinflammatory Plasma Proteins. Journal of Biological Chemistry, 2012, 287, 9708-9721.	3.4	79
16	Exploiting a natural conformational switch to engineer an interleukin-2 "superkine"™. Nature, 2012, 484, 529-533.	27.8	438